Clinical trial NCT03514511: Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis
Official title: Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEO 138559 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Atopic Dermatitis
Lead sponsor: LEO Pharma
Sponsor class: INDUSTRY
First posted: 2018-05-02
Enrollment: 47
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The primary objective of this trial is to investigate the safety and tolerability of LEO 138559 in healthy subjects and subjects with moderate to severe atopic dermatitis.

The secondary objective of this trial is to study the pharmacokinetics and pharmacodynamics following administration of LEO 138559 to healthy subjects and subjects with moderate to severe atopic dermatitis.

Healthy subjects will be exposed to 7 different dose regimens of LEO 138559 (one dose regimen per subject).

Subjects with moderate to severe atopic dermatitis will be exposed to 2 different dose regimens of LEO 138559 (one dose regimen per subject).


Eligibility criteria: Inclusion Criteria:

For healthy subjects and subjects with atopic dermatitis:

* Males and females without childbearing potential.
* Age between 18 and 55, inclusive.
* Body mass index between 18 and 32 kg/m2, inclusive.
* Healthy apart from atopic dermatitis for the subjects presenting the disease.

For subjects with atopic dermatitis only:

* History of atopic dermatitis for more than 6 months.
* Female subjects with childbearing potential and male subjects with female partners with childbearing potential using highly effective contraception from start of the trial and until a period after the last administered dose of trial drug.

Exclusion Criteria:

For healthy subjects and subjects with atopic dermatitis:

* Any significant disease detected prior to enrolment.
* Subjects who are still participating in a clinical trial or who have participated in a clinical trial within 3 months prior to enrolment or within 5 times of the half-life of the experimental therapy, whichever is longer.
* Skin diseases that may interfere with the diagnosis of atopic dermatitis or assessment of the treatment.
* Use of tanning beds or phototherapy within 6 weeks prior to enrolment.
* Subjects with atopic dermatitis requiring more than 3 bleach baths from 4 weeks prior to screening until end of trial.
* Blood pressure or pulse rate outside of the normal range.

For subjects with atopic dermatitis only:

* Initiation of treatment of atopic dermatitis with prescription emollients during the screening period.

Primary outcomes:
measure: Safety of LEO 138559 - numbers of subjects with adverse events
timeFrame: Day 1 to Day 120
measure: Safety of LEO 138559 - number of adverse events
timeFrame: Day 1 to Day 120
measure: Tolerability of LEO 138559 - number of local site reactions
timeFrame: Day 1 to Day 120
Secondary outcomes:
Other outcomes:
Locations:
city: Leeds
country: United Kingdom
facility: Investigational site
city: Liverpool
country: United Kingdom
facility: Investigational site
city: Manchester
country: United Kingdom
facility: LEO Pharma investigational site
Study officials:
affiliation: LEO Pharma
name: Study Director
role: STUDY_DIRECTOR
References: